Dr Vladimir Kirkin's team assesses the activity of novel molecularly targeted anti-cancer agents in preclinical models of cancer – a key requirement for evidence-based drug development.
Dr Vladimir Kirkin studies how anti-cancer agents interact with their molecular targets to stop tumour growth and metastatic spread, and how tumours respond to stress to design new, effective anti-cancer drugs. He has worked for almost a decade in the pharmaceutical industry and contributed to the discovery and early clinical development of a number of molecularly targeted anti-cancer drug candidates.